Middletown, DE, United States of America

Louis Storace

USPTO Granted Patents = 7 (Patent Applications = 1)

CIPO Patents = 3

EPO Patents = 12 (Patent Applications = 10)

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 415(Granted Patents)

Company Filing History:

Dupont Pharmaceuticals Company

patents

1 out of 147

Incyte Holdings Corporation

patents

where one patent can have more than one assignee

Years Active: 2001-2016

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9334274 - N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors (2016-05-10),

2. 8841318 - Substituted heterocycles as janus kinase inhibitors (2014-09-23),

3. 8716303 - N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors (2014-05-06),

4. 8513270 - Substituted heterocycles as Janus kinase inhibitors (2013-08-20),

5. 8415362 - Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors (2013-04-09),

6. 6194569 - Efficient process for the preparation of [S-(R,S)]-N-[1,3-benzodioxol-5-yl)butyl]-3,3-diethyl-2[4-[4-methyl-1-piperazinyl)carbonyl]phenoxy]-4-oxo-1-azetidine carboxamide, a human leukocyte elastase inhibitor (2001-02-27),

7. 6175009 - Process for the preparation of quinazolinones (2001-01-16),

Title: The Innovative Contributions of Louis Storace

Introduction

Louis Storace is a prominent inventor based in Middletown, Delaware, known for his significant contributions to the field of pharmaceuticals. With a total of seven patents to his name, he has made remarkable advancements in the development of Janus kinase inhibitors, which are crucial in treating various diseases.

Latest Patents

Among his latest patents, Storace has developed N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines. These compounds serve as selective JAK1 inhibitors, which are beneficial in treating JAK-associated diseases, including inflammatory and autoimmune disorders, as well as cancer. Additionally, he has patented substituted tricyclic heteroaryl compounds, such as pyridoindoles, pyrimidinoindoles, and triazinoindoles. These compounds modulate the activity of Janus kinases and are useful in treating immune-related diseases, skin disorders, myeloid proliferative disorders, and cancer.

Career Highlights

Throughout his career, Louis Storace has worked with notable companies, including Incyte Corporation and DuPont Pharmaceuticals Company. His work in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Storace has collaborated with esteemed colleagues, including James David Rodgers and Argyrios George Arvanitis. These partnerships have further enhanced his innovative work and expanded the impact of his inventions.

Conclusion

Louis Storace's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a key innovator. His work continues to influence the development of treatments for various diseases, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.